Unstable angina non ST elevation myocardial infarction natural history, complications and prognosis

Jump to navigation Jump to search


Resident
Survival
Guide

Acute Coronary Syndrome Main Page

Unstable angina / NSTEMI Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Unstable Angina
Non-ST Elevation Myocardial Infarction

Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders

Epidemiology and Demographics

Risk Stratification

Natural History, Complications and Prognosis

Special Groups

Women
Heart Failure and Cardiogenic Shock
Perioperative NSTE-ACS Related to Noncardiac Surgery
Stress (Takotsubo) Cardiomyopathy
Diabetes Mellitus
Post CABG Patients
Older Adults
Chronic Kidney Disease
Angiographically Normal Coronary Arteries
Variant (Prinzmetal's) Angina
Substance Abuse
Cardiovascular "Syndrome X"

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Blood Studies
Biomarkers

Electrocardiogram

Chest X Ray

Echocardiography

Coronary Angiography

Treatment

Primary Prevention

Immediate Management

Anti-Ischemic and Analgesic Therapy

Cholesterol Management

Antitplatelet Therapy

Antiplatelet therapy recommendations
Aspirin
Thienopyridines
Glycoprotein IIb/IIIa Inhibitor

Anticoagulant Therapy

Additional Management Considerations for Antiplatelet and Anticoagulant Therapy

Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS

Mechanical Reperfusion

Initial Conservative Versus Initial Invasive Strategies
PCI
CABG

Complications of Bleeding and Transfusion

Discharge Care

Medical Regimen
Post-Discharge Follow-Up
Cardiac Rehabilitation

Long-Term Medical Therapy and Secondary Prevention

ICD implantation within 40 days of myocardial infarction

ICD within 90 days of revascularization

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Unstable angina non ST elevation myocardial infarction natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Unstable angina non ST elevation myocardial infarction natural history, complications and prognosis

CDC onUnstable angina non ST elevation myocardial infarction natural history, complications and prognosis

Unstable angina non ST elevation myocardial infarction natural history, complications and prognosis in the news

Blogs on Unstable angina non ST elevation myocardial infarction natural history, complications and prognosis

to Hospitals Treating Unstable angina non ST elevation myocardial infarction natural history, complications and prognosis

Risk calculators and risk factors for Unstable angina non ST elevation myocardial infarction natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Raviteja Guddeti, M.B.B.S. [3]

Overview

Unstable angina/NSTEMI are signs of severe heart disease. Natural history is complicated by the development of arrhythmias and heart failure. In a study it was shown that 14% of the cases of unstable angina can progress to an MI. Sudden death is an infrequent sequel of both unstable angina and NSTEMI.

Natural History, Complications, and Prognosis

Natural History

Complications

Unstable Angina

List of Factors Affecting the Development and Complications of NSTEMI (In Alphabetical Order)

Prognosis

Unstable Angina

Prognosis in NSTEMI

  • In case of NSTEMI treated non-invasively, elevated levels of high sensitivity troponin T, N-terminal pro-brain natriuretic peptide (NT-proBNP) and growth differentiation factor 15 (GDF-15) are independently associated with an increased risk of myocardial infarction, stroke, and cardiovascular death.
  • In contrast, among patients with NSTEMI treated invasively, elevated levels of only NT-proBNP and GDF-15 have been associated with an increased risk of subsequent myocardial infarction, stroke, and cardiovascular death.[2]

Prediction Rules

References

  1. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM; et al. (2003). "Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18". J Am Coll Cardiol. 41 (8): 1264–72. PMID 12706919.
  2. Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP; et al. (2014). "Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial". Circulation. 129 (3): 293–303. doi:10.1161/CIRCULATIONAHA.113.004420. PMID 24170388.

Template:WH Template:WS